Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corporation is a commercial-stage healthcare company that has developed an immune medicine platform designed to decode the adaptive immune system. The platform combines proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data. This data is used for the diagnosis and treatment of various diseases. The company offers the clonoSEQ diagnostic test, which detects and monitors Minimal Residual Disease (MRD)—the remaining number of cancer cells in a patient's body during and after treatment. Additionally, Adaptive provides products and services for life sciences research, clinical diagnostics, and drug discovery applications.

Adaptive Biotechnologies Corporation is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol ADPT. The company is headquartered in the United States and its financial reporting is conducted in US Dollars (USD). As a US-based company trading on a major US exchange, its stock is traded in USD, making it accessible to investors through standard brokerage accounts that trade US equities.

Adaptive Biotechnologies operates within the Healthcare sector, specifically in the Diagnostics & Research industry. This industry focuses on developing diagnostic tests, research tools, and services that aid in disease detection, monitoring, and drug development. As a diagnostics and research company, Adaptive leverages its immunosequencing platform to provide insights into the adaptive immune system, supporting both clinical diagnostics (such as the clonoSEQ test for cancer monitoring) and research applications for pharmaceutical and academic partners.

Adaptive Biotechnologies Corporation is headquartered in Seattle, Washington, United States. The company was incorporated in 2009 and was originally known as Adaptive TCR Corporation before rebranding to its current name in December 2011. Since its founding, the company has focused on developing its immune medicine platform to decode the adaptive immune system. Its location in Seattle places it within a vibrant biotechnology and life sciences ecosystem, which supports its research and development efforts in immunology and diagnostics.